A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

January 15, 2026

Primary Completion Date

June 1, 2030

Study Completion Date

June 1, 2030

Conditions

Autosomal Dominant Alzheimers DiseaseEarly Onset Alzheimer DiseaseAlzheimers Disease

Interventions

DRUG

Donanemab

IV Infusion

DRUG

RG6289

Oral tablet

DRUG

Donanemab placebo

IV placebo

DRUG

RG6289 placebo

Oral tablet placebo

Trial Locations (1)

Neurosciences Group of Antioquia, University of Antioquia, Medellín